8 years in the making – and just 2 months after FDA clearance – and the big moment is finally here! The first-ever commercial shipment of the TriVerity test system, which includes TriVerity Cartridges and the Myrna Instrument, left our HQ and got delivered to our first customer! This groundbreaking milestone would not be possible without the incredible years of dedication and meticulous work from so many on #TeamInflammatix. Now, the next phase of our work truly begins – to transform emergency medicine and improve patient care through advanced interpretation of the immune response. With #TriVerity, we’re ushering in a paradigm shift in rapid infection diagnosis and health system resource management. The journey ahead is incredibly exciting, and we can’t wait for the profound difference we’ll make together! #EmergencyMedicine #HostResponse #Diagnostics #InfectionManagement #Sepsis #EmergencyMed #IVD #HealthcareInnovation #HealthcareTransformation #PatientCare
Inflammatix, Inc.
生物技术研究
Sunnyvale，California 8,268 位关注者
We’re reimagining diagnostics by reading the immune system
关于我们
Inflammatix, Inc., based in Sunnyvale, California, USA, is revolutionizing molecular diagnostics with machine-learning-powered technology to rapidly read a patient’s immune response to improve patient care and reduce major public health burdens. It’s flagship in vitro diagnostic (IVD) test, the TriVerity? Test System (“TriVerity”) shows the likelihood of a bacterial infection, a viral infection, and illness severity in adult patients with suspected acute infection or sepsis that present to emergency departments. TriVerity empowers physicians to confidently make care decisions, which could influence the selection of antimicrobial therapy, focused workups with judicious laboratory and imaging orders, and patient admission or discharge disposition. TriVerity and future tests are designed to be performed on the company’s proprietary Myrna? instrument, a cartridge-based benchtop analyzer that is capable of multiplex sample-to-answer quantitation of mRNA in about 30 minutes.
- 网站
-
https://www.inflammatix.com
Inflammatix, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Sunnyvale，California
- 类型
- 私人持股
- 创立
- 2016
- 领域
- Molecular Diagnostics、Biotechnology、Computational Immunology、in-vitro diagnostics、Personalized Medicine和Bioinformatics
地点
-
主要
获取路线
540 Oakmead Pkwy
US，California，Sunnyvale，94085
Inflammatix, Inc.员工
动态
-
Traditional diagnostic methods take hours—time that critically ill patients don’t have. What if we could decode the immune system’s response through gene expression—before any traditional test results came back? Inflammatix, Inc. is making this a reality and QIAGEN Genomic Services were proud to support this breakthrough, providing the genomic expertise and tools needed to bring their vision to life. As part of this process, the use of QIAGEN PAXgene? Blood RNA tubes ensured high-quality RNA stabilization for accurate gene expression analysis. Innovative breakthroughs need the right support—and we’re excited to be part of this story. Watch how it all comes together.
-
Our Co-Founder and Chief Scientist Purvesh Khatri will participate in a panel discussion at the 32nd International Precision Med TRI-CON, in a session entitled, “Host Response Profiling in Infectious Diseases.” Advanced host-response diagnostics are transforming the way we detect infections, moving beyond traditional blunt biomarkers and pathogen-based tests to focus on how the body specifically responds to infection. This shift is critical for improving diagnosis, guiding precision treatment, and reducing antibiotic misuse. See session details here: https://lnkd.in/ec4zpCSW
-
-
It’s IHI Patient Safety Awareness Week, a time to spotlight the importance of safety in healthcare settings. Our team at Inflammatix is committed to offering the healthcare community better tools to improve patient safety in patients suspected of acute infections and sepsis. With immune host response technology, we can enable earlier detection and more precisely targeted intervention that may lead to a future with improved outcomes, including lower mortality. #PatientSafety ?#sepsis
-
-
Don't miss this manuscript to learn more of what Tim and Ljubomir are talking about! https://lnkd.in/etQwgB4K
Volume 259 The Proceedings of Machine Learning for Health 2024 https://lnkd.in/eAKeg9Bi Is now available on PMLR.
-
This editor’s choice study in Critical Care Medicine, the journal of the Society of Critical Care Medicine, reinforces that sepsis treatment is not one-size-fits-all. The latest research highlights the wide variability in treatment response among sepsis patients - underscoring the urgent need for precision medicine in critical care. We have been at the forefront of #sepsis subtypes (or ‘endotypes’) research. By leveraging gene expression, we aim to move beyond blanket treatment approaches, with the goal of guiding clinicians to the right treatment for the right patient at the right time. Learn more at https://lnkd.in/e_USuUyP Read the study: https://lnkd.in/d4-fiaN4 #PrecisionMedicine
-
Attending the Society of Critical Care Medicine Critical Care Congress, February 23-25, 2025 in Orlando, FL? Our CEO and Co-Founder Tim Sweeney will deliver an oral presentation on TriVerity, our FDA-cleared molecular blood test for adult emergency department patients suspected of acute infection or sepsis #SCCM2025. Check out this Research Snapshot Theater session to learn more. You can register here https://lnkd.in/dcPuPZmq
-
-
We thank our partner QIAGEN for capturing the Inflammatix story! We have relied on Qiagen to run NGS samples for TriVerity and other products in our pipeline, to reliably measure the level gene expressions associated with patients’ immune response. Please click on the link provided down below to read and watch video to learn more on how TriVerity can help transform emergency medicine. #PrecisionMedicine #HealthcareInnovation
Imagine a moment when a patient’s life is in your hands. But you have no fast, reliable way to figure out what’s wrong. Is it a life-threatening infection that needs urgent treatment, or just a natural immune response after surgery? Hours of waiting for test results could mean the difference between life and death. ? This was the challenge that Tim Sweeney, physician and researcher, faced time and time again. He realized that traditional diagnostic methods were slow and often inaccurate—and in some cases, by the time a definitive diagnosis was made, it was already too late. ? But what if we could decode the immune system’s response through gene expression—before any traditional test results came back? ? How did Sweeney crack this puzzle? ?? https://lnkd.in/eY7y-8qB
-
-
Combining molecular science with AI-powered diagnostics could provide more rapid, actionable insights into bacterial and viral infections—and predict the likelihood of critical illness before it’s too late. See commentary from our CEO and Co-Founder Tim Sweeney in this Science News Magazine January 2025 feature about the potential of AI to reshape healthcare [section "AI could calculate health risks from patient data"]. Access the full article here: https://lnkd.in/enW9wyBW
-
Thank you Stanford Medicine for interviewing Purvesh Khatri to tell the TriVerity story - following its recent FDA clearance - which started in Dr. Khatri's lab with Tim Sweeney a decade ago. Their pioneering work led them and Jonathan Romanowsky to cofound Inflammatix in 2016. It's a great article in SCOPE - give it a read!
A new sepsis test developed at Stanford Medicine uses machine learning and publicly available medical datasets from around the world to speed up life-saving diagnoses. https://stan.md/4aRZs8E?
-